- Home
- LPX vs TFX Comparison
LPX vs TFX Comparison
Compare LPX & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPX
- TFX
- Stock Information
- Founded
- LPX 1973
- TFX 1943
- Country
- LPX United States
- TFX United States
- Employees
- LPX N/A
- TFX N/A
- Industry
- LPX Forest Products
- TFX Medical/Dental Instruments
- Sector
- LPX Basic Materials
- TFX Health Care
- Exchange
- LPX Nasdaq
- TFX Nasdaq
- Market Cap
- LPX 8.1B
- TFX 8.3B
- IPO Year
- LPX N/A
- TFX N/A
- Fundamental
- Price
- LPX $98.70
- TFX $175.43
- Analyst Decision
- LPX Hold
- TFX Buy
- Analyst Count
- LPX 9
- TFX 7
- Target Price
- LPX $108.75
- TFX $252.50
- AVG Volume (30 Days)
- LPX 661.6K
- TFX 498.9K
- Earning Date
- LPX 02-19-2025
- TFX 02-27-2025
- Dividend Yield
- LPX 1.13%
- TFX 0.77%
- EPS Growth
- LPX 139.43
- TFX N/A
- EPS
- LPX 5.89
- TFX 5.03
- Revenue
- LPX $2,941,000,000.00
- TFX $3,025,824,000.00
- Revenue This Year
- LPX N/A
- TFX $4.56
- Revenue Next Year
- LPX N/A
- TFX $4.63
- P/E Ratio
- LPX $16.77
- TFX $34.93
- Revenue Growth
- LPX 13.95
- TFX 2.27
- 52 Week Low
- LPX $69.90
- TFX $165.62
- 52 Week High
- LPX $122.87
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- LPX 25.93
- TFX 50.59
- Support Level
- LPX $97.90
- TFX $165.62
- Resistance Level
- LPX $114.19
- TFX $176.71
- Average True Range (ATR)
- LPX 3.87
- TFX 3.46
- MACD
- LPX -2.06
- TFX 0.50
- Stochastic Oscillator
- LPX 4.11
- TFX 70.58
About LPX Louisiana-Pacific Corporation
Louisiana-Pacific is primarily an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The company is largely exposed to the North American housing market but has also established capacity in Brazil and Chile.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.